Thermo Fisher Scientific Inc.

Healthcare | Medical Laboratories & Research | USA
Thermo Fisher beats Q4 consensus

...

Thermo Fisher Scientific (TMO) Q4 results: Revenues: $6,507M (+7.6%); Life Sciences Solutions: $1,697M (+7.5%); Analytical Instruments: $1,568M (+10.9%); Specialty Diagnostics: $951M (+4.0%); Laboratory Products and Services: $2,602M (+8.4%).

Net Income: $898M (+69.4%); Non-GAAP Net Income: $1,317M (+16.8%); EPS: $2.22 (+69.5%); Non-GAAP EPS: $3.25 (+16.5%); CF Flow Ops: $4,543M (+13.4%).

...

https://www.investing.com/news/stock-mar...us-1762970

Thermo Fisher Scientific Earnings, Revenue Beat in Q1

...

The firm reported earnings per share of $2.81 on revenue of $6.13B. Analysts polled by Investing.com anticipated EPS of $2.73 on revenue of $6.02B. That compared to EPS of $2.5 on revenue of $5.85B in the same period a year earlier. The company had reported EPS of $3.25 on revenue of $6.51B in the previous quarter.

...

https://www.investing.com/news/stock-mar...q1-1844060

Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance

Thermo Fisher Scientific Inc.'s TMO third-quarter 2019 adjusted earnings per share (EPS) came in at $2.94, beating the Zacks Consensus Estimate by 2.1%. The figure also improved from the year-ago quarterly figure by 12.2%. On a reported basis, EPS was $1.88, up 7.4% year over year.

Revenues in the quarter under review grossed $6.27 billion, up 5.9% year over year. The top line also beat the Zacks Consensus Estimate by 1.3%.


...

https://finance.yahoo.com/news/thermo-fi...01755.html

Thermo Fisher Scientific (TMO) Q4 Earnings and Revenues Surpass Estimates

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $3.55 per share, beating the Zacks Consensus Estimate of $3.54 per share. This compares to earnings of $3.25 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 0.28%. A quarter ago, it was expected that this maker of scientific instrument and laboratory supplies would post earnings of $2.88 per share when it actually produced earnings of $2.94, delivering a surprise of 2.08%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Thermo Fisher, which belongs to the Zacks Medical - Instruments industry, posted revenues of $6.83 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.67%. This compares to year-ago revenues of $6.51 billion.


...

https://finance.yahoo.com/news/thermo-fi...12783.html

Thermo Fisher (TMO) Q2 Earnings Beat on COVID-19-Led Sales

Thermo Fisher Scientific Inc.'s TMO second-quarter 2020 adjusted earnings per share of $3.89 beat the Zacks Consensus Estimate by 45.7%. The figure improved 27.9% year over year. The adjusted number excludes certain non-recurring expenses including, asset amortization costs and certain restructuring costs.

On a reported basis, earnings per share were $2.90, up 4.7% year over year.

Revenues in the quarter under review grossed $6.92 billion, up 9.5% year over year. The top line edged past the Zacks Consensus Estimate by 0.1%.


...

https://finance.yahoo.com/news/thermo-fi...02270.html

Der weltgrößte Medizintechnik-Ausrüster und Analyseverfahrens-Entwickler THERMO FISHER SCIENTIFIC (US8835561023 / + 6,8 %) profitierte hingegen von einer neuen Studie des renommierten internationalen Technologie-Marktforschungsinstituts Technavio, nach der der Weltmarkt für Gentestverfahren von 2020 - 2024 weiter sehr robust um ca. 12 % p.a. sowie auch der Absatzmarkt für medizinische Testgeräte im gleichen Zeitraum um ca. 5 % p.a. wachsen sollte.

Für beide hoch stabilen Marktausweitungen sieht Technavio Thermo Fisher derzeit als einen der weltweit Hauptbegünstigten dieses anhaltenden Wachstumstrends an. ntg24

Läufer


WASHINGTON (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO) said Monday it has received an expansion of its Emergency Use Authorization or EUA for the TaqPath COVID-19 Combo Kit to include an additional sample collection method provided by Everlywell, a digital health testing company.

The TaqPath test is authorized for use with the Everlywell COVID-19 Test Home Collection Kit. This will enable individuals to self-collect nasal swab specimens after it is determined by a healthcare provider to be appropriate, based on results of a COVID-19 questionnaire.

Samples collected using the Everlywell self-collection kit may be processed by CLIA-certified laboratories running Thermo Fisher's TaqMan SARS-CoV-2 RNase P Assay Kit. The results can be obtained through the Everlywell online platform.

'As part of our commitment to keep our workplaces safe and healthy, Thermo Fisher launched its own pilot program to provide at-home collection kits and online access to test results for more than 10,000 colleagues across the country. Now, leveraging Everlywell's capabilities, we can expand our own use and offer other organizations the confidence to move forward with return-to-workplace strategies that reduce the risk of spreading the virus,' said Mark Stevenson, executive vice president and chief operating officer at Thermo Fisher Scientific.

Finanznachrichten.de

Zahlen

https://seekingalpha.com/news/3624066-th...on-revenue

Thermo Fisher Scientific-Aktien haben in den vergangenen zehn Jahren per saldo +964,0% an Wert gewonnen, was einer jährlichen Performance von im Mittel +26,7% entspricht. Aus einem Investment in Höhe von 10.000 US-Dollar wären 106.404 US-Dollar geworden. Parallel dazu ist das Anlagerisiko als deutlich unterdurchschnittlich einzuordnen (Verlust-Ratio*: 1,37). 



https://www.boerse.de/aktien/Thermo-Fish...8835561023

Guten Morgen,
ich habe Thermo Fisher abgeklopft und mal wieder festgestellt das es ein sehr gute Firma ist!
Momentan sehe ich sogar eine gute Einstiegs- oder Nachkaufgelegenheit.
Charttechnisch wurde das steigende rechtwinklige Dreieck nach oben durchbrochen bei steigendem Umsatz, was sehr Positiv ist.
Achtung mein chart ist in €!